JP2014530835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530835A5 JP2014530835A5 JP2014536235A JP2014536235A JP2014530835A5 JP 2014530835 A5 JP2014530835 A5 JP 2014530835A5 JP 2014536235 A JP2014536235 A JP 2014536235A JP 2014536235 A JP2014536235 A JP 2014536235A JP 2014530835 A5 JP2014530835 A5 JP 2014530835A5
- Authority
- JP
- Japan
- Prior art keywords
- blood lymphocyte
- patient
- dosage
- lymphocyte count
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004698 Lymphocytes Anatomy 0.000 claims description 141
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims description 106
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims description 106
- 230000000051 modifying Effects 0.000 claims description 57
- 239000000018 receptor agonist Substances 0.000 claims description 57
- 230000001939 inductive effect Effects 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 210000004027 cells Anatomy 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000011780 sodium chloride Substances 0.000 claims description 26
- 239000000651 prodrug Substances 0.000 claims description 23
- 229940002612 prodrugs Drugs 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- KIHYPELVXPAIDH-UHFFFAOYSA-N 1-[[4-[N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical group CCC1=CC(C(C)=NOCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 206010003816 Autoimmune disease Diseases 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000005418 aryl aryl group Chemical group 0.000 claims description 4
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- -1 1H- tetrazol-5-yl Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims description 2
- 125000004429 atoms Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 2
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 35
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 229940079593 drugs Drugs 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 description 11
- 239000000243 solution Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549847P | 2011-10-21 | 2011-10-21 | |
| US61/549,847 | 2011-10-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530835A JP2014530835A (ja) | 2014-11-20 |
| JP2014530835A5 true JP2014530835A5 (zh) | 2016-06-02 |
Family
ID=47022722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536235A Pending JP2014530835A (ja) | 2011-10-21 | 2012-10-18 | Ｓ１ｐ受容体モジュレーターまたはｓ１ｐ受容体アゴニストのための投薬量レジメン |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20150218090A1 (zh) |
| EP (1) | EP2768494A1 (zh) |
| JP (1) | JP2014530835A (zh) |
| KR (1) | KR20140084041A (zh) |
| CN (1) | CN103889408A (zh) |
| AU (1) | AU2012324867B2 (zh) |
| BR (1) | BR112014009141A8 (zh) |
| CA (1) | CA2852142A1 (zh) |
| CL (1) | CL2014000991A1 (zh) |
| IL (1) | IL231945A0 (zh) |
| MX (1) | MX2014004813A (zh) |
| RU (1) | RU2014120411A (zh) |
| SG (2) | SG11201401065RA (zh) |
| TN (1) | TN2014000132A1 (zh) |
| TW (1) | TW201320998A (zh) |
| WO (1) | WO2013057212A1 (zh) |
| ZA (1) | ZA201402283B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170027907A1 (en) * | 2014-04-10 | 2017-02-02 | Eric Legangneux | Sip modulator immediate release dosage regimen |
| EP3168237A1 (en) * | 2015-11-10 | 2017-05-17 | Dow Global Technologies LLC | High pressure, free radical polymerizations to produce ethylene-based polymers |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| AU2020372647A1 (en) | 2019-10-31 | 2022-06-16 | Idorsia Pharmaceuticals Ltd | Combination of a CXCR7 antagonist with an S1P1 receptor modulator |
| US20230295076A1 (en) * | 2020-08-20 | 2023-09-21 | Medshine Discovery Inc. | Acetophenone oxime compound and application thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2483594C (en) | 2002-05-16 | 2011-02-15 | Novartis Ag | Use of edg receptor binding agents in cancer |
| CA2524054C (en) * | 2003-05-19 | 2012-04-24 | Irm Llc | Immunosuppressant compounds and compositions |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| AU2004251146A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
| UA74941C2 (en) | 2004-04-26 | 2006-02-15 | Fos Internat S A | A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same |
| WO2006058316A1 (en) * | 2004-11-29 | 2006-06-01 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| PT2952177T (pt) * | 2007-10-12 | 2021-04-26 | Novartis Ag | Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p) |
| JO3044B1 (ar) * | 2008-12-22 | 2016-09-05 | Novartis Ag | نظام تناول جرعة لمنبه مستقبل s1p |
| EP2482810A2 (en) * | 2009-09-29 | 2012-08-08 | Novartis AG | Dosage regimen of an s1p receptor modulator |
-
2012
- 2012-10-18 JP JP2014536235A patent/JP2014530835A/ja active Pending
- 2012-10-18 US US14/250,550 patent/US20150218090A1/en not_active Abandoned
- 2012-10-18 MX MX2014004813A patent/MX2014004813A/es unknown
- 2012-10-18 WO PCT/EP2012/070692 patent/WO2013057212A1/en active Application Filing
- 2012-10-18 RU RU2014120411/15A patent/RU2014120411A/ru not_active Application Discontinuation
- 2012-10-18 AU AU2012324867A patent/AU2012324867B2/en not_active Ceased
- 2012-10-18 BR BR112014009141A patent/BR112014009141A8/pt active Search and Examination
- 2012-10-18 SG SG11201401065RA patent/SG11201401065RA/en unknown
- 2012-10-18 KR KR1020147010157A patent/KR20140084041A/ko not_active Application Discontinuation
- 2012-10-18 CA CA2852142A patent/CA2852142A1/en not_active Abandoned
- 2012-10-18 CN CN201280051765.7A patent/CN103889408A/zh active Pending
- 2012-10-18 EP EP12772986.1A patent/EP2768494A1/en not_active Withdrawn
- 2012-10-18 SG SG10201602279PA patent/SG10201602279PA/en unknown
- 2012-10-19 TW TW101138798A patent/TW201320998A/zh unknown
-
2014
- 2014-03-27 ZA ZA2014/02283A patent/ZA201402283B/en unknown
- 2014-03-28 TN TNP2014000132A patent/TN2014000132A1/en unknown
- 2014-04-03 IL IL231945A patent/IL231945A0/en unknown
- 2014-04-17 CL CL2014000991A patent/CL2014000991A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012321110B2 (en) | Combination treatment | |
| JP6159958B2 (ja) | 癌または前癌状態を治療するための組み合わせ方法 | |
| JP2014530835A5 (zh) | ||
| JP5188003B2 (ja) | プロポフォールの水溶性プロドラッグを含む薬学的組成物およびその投与方法 | |
| RU2007124327A (ru) | Курс лечения с использованием агониста рецептора s1p | |
| AU2015371175B2 (en) | Use of isoxazoline compounds for treating demodicosis | |
| KR20170123724A (ko) | 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형 | |
| MX2010012358A (es) | Tratamientos para el mieloma multiple. | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| US20200383983A1 (en) | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo | |
| JP2018531605A5 (zh) | ||
| EP1977745B1 (en) | Treatment of incontinence | |
| RU2014120411A (ru) | Схема приема модулятора или агониста рецептора s1p | |
| RU2015141151A (ru) | Идентификация реакции пациентов на введение модулятора рецепторов s1p | |
| JP2020520374A (ja) | 関節リウマチの治療用組成物および治療方法 | |
| US9987301B2 (en) | Heparin-based compositions and methods for the inhibition of metastasis | |
| RU2012106827A (ru) | Применение производных 5н-дибенз/в, f/азепин-5-карбоксамида для лечения фибромиалгии | |
| CA2482687A1 (en) | Treatment of mesothelioma | |
| KR20080096829A (ko) | 정맥내 항바이러스 치료 | |
| RU2604132C2 (ru) | Фармацевтическая композиция для профилактики или лечения гипертриглицеридемии или вызванных гипертриглицеридемией заболеваний | |
| WO2020196463A1 (ja) | 顎骨壊死の予防又は治療剤 | |
| AU2016253153A1 (en) | Compositions for the treatment of cancer | |
| RU2017132445A (ru) | Дозы панобиностата для множественной миеломы | |
| RU2022131081A (ru) | Идентификация реакции пациентов на введение модулятора рецепторов s1p |